Mounjaro®
Starting from £179.99/mo
Start journey Learn moreInjecting Wegovy above the belly button is not recommended. The approved abdominal injection zone sits below the navel, and official guidance asks patients to keep a two-inch (roughly 5 cm) clearance from the belly button itself. That boundary exists for a clinical reason, not an arbitrary one — and understanding it takes about two minutes. If you're asking because you're unsure exactly where on your body to inject, you're in good company; it's one of the questions our prescribers field most weeks. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber reviews every patient's treatment before dispensing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy SmPC and Patient Information Leaflet, published on the Electronic Medicines Compendium (eMC), are clear: when using the abdomen, choose the area around the lower abdomen. That means below the navel, not above it. A minimum clearance of about 5 cm from the belly button is the standard instruction, applicable to both the area directly above and the ring around it.
The reasoning is straightforward. Skin thickness and subcutaneous fat distribution vary considerably in the tissue directly around and above the navel. Thinner subcutaneous layers mean a higher chance of an intramuscular injection rather than the subcutaneous one the pen is designed to deliver. An intramuscular injection changes the absorption profile: the medicine enters the bloodstream faster than intended, which can increase side-effect intensity without improving efficacy.
Above the belly button, the skin is also closer to the fascial layer covering abdominal muscles. Injecting there is more likely to cause localised pain, bruising and site reactions. None of those outcomes are dangerous in isolation, but they are avoidable. The guidance exists precisely because patients tested these limits in early clinical work, and the lower abdomen consistently gave better tolerability and more predictable results.
The full Wegovy injection technique guide on our site walks through pen preparation, pinch technique and the post-injection hold step, which matters more than many people realise.
If the lower abdomen is uncomfortable (scar tissue, skin sensitivity, or simply running out of usable rotation spots) two other sites are licensed for Wegovy: the front or outer thigh, and the outer area of the upper arm. Rotating weekly between sites (and within a site) prevents the build-up of lipohypertrophy, the small lumps of thickened tissue that develop if the same spot is used repeatedly.
Thigh injections are easy to self-administer and give good subcutaneous access for most people. The stomach versus thigh comparison covers what trial data and prescriber experience suggest about site preference, though the honest answer is that individual anatomy matters more than any general ranking.
The upper arm is a licensed option too, though it requires some flexibility to reach the outer aspect cleanly. Many patients find a household member or partner can help if self-injection there proves awkward. Details on arm injection are covered in our guide to upper-arm Wegovy injections. Some patients also ask about the gluteal area; the guide on that site explains what the SmPC says.
One rule applies regardless of site: never inject into skin that is broken, bruised, tender or affected by any skin condition. Rotate spots within each site by at least a few centimetres from the previous injection mark.
A rotation map sounds clinical, but in practice it just means varying your spot each week rather than returning to whichever area felt easiest last time. With a once-weekly injection schedule, a simple mental note or a small drawn grid on paper is usually enough to track where you last injected.
Clean the site with an alcohol swab and allow it to dry fully before injecting, wet alcohol on the skin stings on needle entry. The pinch technique (lifting a fold of skin between two fingers) helps ensure the needle reaches subcutaneous tissue rather than muscle, particularly on leaner patients. Hold the pen in place for the full count after injecting; removing it early can allow medicine to leak back along the needle track.
According to NHS guidance on semaglutide, if you notice persistent redness, swelling or a lump at any injection site that does not resolve within a few days, contact your prescriber or GP. Site reactions are the most common injection-related complaint and are nearly always avoidable with good rotation.
Timing your injection is a separate question from where to do it. If you're uncertain whether to shift your injection day or inject at a different time of day, the guide on early injection timing and the evening injection guide address those questions directly.
Most injection-site questions have clear answers in the Patient Information Leaflet. A few don't. If you have abdominal surgery scars, stomas, skin conditions like psoriasis or eczema, or significant variation in body composition, the standard guidance may not translate cleanly to your anatomy. That's a conversation for your prescriber, not a search result.
Wegovy is a prescription-only medicine. At nume, every patient's treatment is reviewed before each supply by a GPhC-registered Independent Prescriber, not automated software. If your injection-site question comes up during that review, or through our aftercare team, you'll get a specific answer rather than a general one. If you're still exploring whether Wegovy is the right treatment for you, the Wegovy overview covers licensing, eligibility and what to expect. For a broader look at the treatment options available at nume, that page compares approaches. When you're ready, you can check your eligibility through a free consultation, reviewed the same day by a named prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.